[HTML] from ascopubs.orgGK Ellis, WE Barlow, JR Gralow… - Journal of Clinical …, 2011 - jco.ascopubs.org Purpose Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral ... Related articles - All 7 versions
[PDF] from hematologylibrary.orgD Neuberg, IW Flinn, MR Grever… - 2011 - bloodjournal.hematologylibrary.org Mitchell R. Smith, MD, Ph.D.1 Donna Neuberg, Sc.D.2 Ian W. Flinn, MD3 Michael R. Grever, MD 4 Hillard M. Lazarus, MD5 Jacob M. Rowe, MD6 Gordon Dewald, Ph.D.7* John M. Bennett, MD8 Elisabeth M. Paietta, Ph.D. 9 John C. Byrd, MD4 Mohamad A. Hussein, ... View as HTML
P Rastogi, ME Buyse, SM Swain… - Clinical breast …, 2011 - ncbi.nlm.nih.gov BACKGROUND: Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer (MBC). The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast ... All 2 versions
G Schiavoni, A Sistigu, M Valentini, F Mattei… - Cancer research, 2011 - AACR Successful chemotherapy accounts for both tumor-related factors and host immune response. Compelling evidence suggests that some chemotherapeutic agents can induce an immunogenic type of cell death stimulating tumor-specific immunity. Here, we show that ... Cited by 4 - Related articles - All 4 versions
MR Smith, D Neuberg, IW Flinn, MR Grever… - Blood, 2011 - ncbi.nlm.nih.gov Chemotherapy related myeloid neoplasia (t-MN) is a significant late toxicity concern after cancer therapy. In the randomized intergroup Phase III E2997 trial, initial therapy of CLL with fludarabine and cyclophosphamide (FC) compared with fludarabine (F) alone yielded higher ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
